Neuland Laboratories reported mixed financial results for Q3FY26 and conducted its earnings conference call on February 9, 2026, where management discussed the company's performance, strategic investments, and future growth prospects. The pharmaceutical company demonstrated revenue growth but faced margin pressures due to product mix challenges and higher operating expenses.

Q3FY26 Financial Performance

The company's total income for Q3FY26 reached Rs. 447.8 crore, marking an 11.4% year-on-year increase from Rs. 401.9 crore in Q3FY25. However, profitability metrics showed contrasting trends with EBITDA declining to Rs. 85.0 crore compared to Rs. 90.3 crore in the previous year.

Nine-Month Performance Overview

For the nine-month period ending December 31, 2025, Neuland Laboratories demonstrated steady revenue growth with total income rising 8.9% to Rs. 1,264.5 crore from Rs. 1,160.9 crore in the corresponding period last year.

Management Commentary on Business Performance

During the earnings call, CFO Abhijit Majumdar explained that commercial CMS projects contributed over 50% of revenue for the quarter. The lower EBITDA margin of 19% was attributed to reduced gross margins and increased overheads, including a Rs. 10 crore impact from labor codes. Without this impact, EBITDA would have stood at Rs. 95 crore with a 21% margin.

Vice Chairman and Managing Director Saharsh Davuluri noted that while revenues aligned with annual outlook, product mix within businesses and increased operating expenses impacted EBITDA margins. He emphasized that the quarter's performance was "in line with expectations" despite lower margins.

Strategic Investments and Capacity Expansion

The company reported significant operational developments including working capital improvement to 145 days of sales in Q3FY26 from 155 days in Q2FY26. Capital expenditure outflow reached Rs. 254.0 crore during 9MFY26, supporting future growth plans.

CDMO Business and Future Outlook

Management highlighted increasing customer interest in the company's capabilities as a proven commercial NCE drug substance manufacturer. The CDMO business transition has evolved over decades, with majority revenues now derived from human health-focused CDMO operations.

Saharsh Davuluri emphasized the company's positioning for "decadal growth," projecting potential for 20-plus CAGR from 2026 to 2036. He noted that growth for the next 2-3 years is "preordained" by existing products requiring execution, while peptide investments target growth beyond the 3-year period.

Peptide Manufacturing Initiative

The company reported strong traction in peptide CDMO capabilities, with 5-6 innovators approaching Neuland with peptide projects during the year. Management expressed confidence in securing at least one commercial manufacturing arrangement for a peptide NCE in FY27, supported by the large-scale peptide manufacturing facility ready for commissioning in July.

Earnings Call Transcript Release

Neuland Laboratories filed the complete earnings call transcript with BSE and NSE on February 13, 2026, pursuant to Regulation 30 of SEBI regulations. The transcript has been made available on the company's website for investor access.

Neuland laboratories has announced that its Board of Directors will convene on February 9, 2026, to approve the company's unaudited financial results for the third quarter of fiscal year 2026. The pharmaceutical company made this announcement on January 21, 2026, in compliance with Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The scheduled board meeting will focus on approving and taking on record the unaudited financial results for both standalone and consolidated operations. The results will cover the quarter and nine months ended December 31, 2025.

Trading Window Restrictions

In accordance with the company's Insider Trading Code, Neuland Laboratories has implemented trading window restrictions for its equity shares. The trading window closure, which began on January 1, 2026, will remain in effect until 48 hours after the declaration of the unaudited financial results to the stock exchanges.

This measure ensures compliance with insider trading regulations and maintains market integrity during the financial results announcement period. The company had previously communicated about these restrictions in a letter dated December 26, 2025.

Regulatory Compliance

The announcement demonstrates Neuland Laboratories' commitment to maintaining transparency and adhering to regulatory requirements. Company Secretary Sarada Bhamidipati signed the official communication, which was addressed to both BSE Limited and The National Stock Exchange of India Ltd.

The notification serves as formal intimation to stakeholders about the upcoming financial disclosure and ensures all regulatory protocols are followed in accordance with SEBI guidelines.